FOS and prostate carcinoma: The activation of MAPK/ERK results in activation of the transcription factor AP-1, a heterodimer of Fos and Jun family proteins, and it was documented that AEG-1 knockdown results in a marked inhibition of AP-1 DNA binding in prostate cancer cells [196].